* Bristol-Myers squibb and abbvie announce european
commission approval of empliciti(tm) (elotuzumab) for the
treatment of multiple myeloma in adult patients who have
received at least one prior…
The post BRIEF-Bristol-Myers says European Commission approval of Empliciti for treatment of multiple myeloma appeared first on NASDAQ.